What You Should Know:
- The Israel Advanced Technologies Institute (IATI), in partnership with PwC and the Israel Innovation Authority, unveiled its annual Life Science Industry report at the MIXiii Health-Tech.IL conference.
- The report underlines the Israeli life sciences sector's resilience, unity, and determination to keep operating, innovating, and delivering crucial solutions. While acknowledging the current challenges, the research underscores the importance of continued support
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Lexaria Conducts Second Human Trial for Improved Oral GLP-1 Delivery
What You Should Know:
- Lexaria Bioscience Corp. is pushing the boundaries of oral drug delivery with their latest clinical trial.
- The company announced they have contracted a research organization (CRO) to conduct a second human pilot study on their DehydraTECH-powered glucagon-like peptide-1 (GLP-1) treatment.
GLP-1 Challenges and Lexaria's Solution
GLP-1 drugs, like semaglutide, are currently delivered through injections or tablets. However, these methods have limitations.
Read More
Panacea Launches Whole Exome Sequencing
What You Should Know:
- Panacea, the genetic health services provider, announces nationwide commercial availability, enabling consumers to access potentially life-saving testing without doctor visits or insurance approval.
- Offering whole exome sequencing, Panacea conducts in-depth analysis of every human gene, aiding in the identification of disease-driving mutations for proactive disease management.
- With nearly half of Americans facing cancer risk, approximately 20 million
Read More
ArteraAI’s Prostate Test Earns Recognition in NCCN Guidelines for Prostate Cancer
What You Should Know:
- ArteraAI, a leader in artificial intelligence (AI)-powered cancer tests, today announced a significant achievement – the inclusion of their ArteraAI Prostate Test in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer.
- This marks a major milestone for ArteraAI, solidifying its position at the forefront of AI-driven oncology and personalized patient care.
A First for AI-powered Testing
The ArteraAI Prostate Test is the
Read More
Absci Announces $75M Public Offering to Fuel AI Drug Creation
What You Should Know:
- Absci Corporation (Nasdaq: ABSI), a company utilizing generative AI for drug discovery, announced today an initial public offering (IPO) of $75 million in common stock.
- This IPO aims to support the advancement of Absci's internal drug development programs, further investment in their Integrated Drug Creation™ platform, and general corporate purposes.
Offering Details
Absci intends to offer $75M of common stock, with an option to sell an additional $11.25M
Read More
Veradigm Acquires ScienceIO for $140M in Cash to Accelerate AI Innovation in Healthcare
What You Should Know:
- Veradigm Inc. (NASDAQ: MDRX), a provider of healthcare data and technology solutions, announced an agreement to acquire ScienceIO, a leader in healthcare AI platform and foundation models.
- The acquisition is valued at $140 million in cash, with $44 million deferred and payable in installments over three years. Veradigm will fund the transaction entirely from existing cash reserves.
Strategic Acquisition to Enhance AI Capabilities
This acquisition signifies
Read More
How to Use NBA in Pharma Sales: Best Practices
Next Best Action has been one of the most important approaches for sales in recent years, including for pharmaceuticals. But because selling pharma is significantly different than selling other products, pharma-oriented NBA approaches need to be significantly more sophisticated than NBA for other industries. Pharma sales teams looking to implement NBA need to embrace an updated, data-driven version of this approach, known as NBA 2.0,
Read More
Alamar Biosciences Raises $128M to Accelerate Proteomics Platform
What You Should Know:
- Alamar Biosciences, a leader in precision proteomics for early disease detection raises $100M in Series C round, with an additional $28M expected within the next 30 days. This brings their total funding to nearly $250M.
- The Series C funding round was led by led by Sands Capital, with participation from new and existing investors, including both financial and strategic partners. Ian Ratcliffe, Executive Managing Partner at Sands Capital, has joined Alamar's Board
Read More
Power Secures $11.9M to Democratize Clinical Trials
What You Should Know:
- Power, the company transforming the traditional clinical trial landscape, announced today the close of their $11.9M Series A funding round led by Kin, Contrary, and Footwork.
- The strategic funding fuels Power's mission to democratize access to clinical trials and diversify the pool of participants, ultimately accelerating life-saving medical research.
Revolutionizing Clinical Trial Participation
Founded in 2021 by Brandon Li and Michael Gill, Power
Read More
FDA Clears Proscia’s Digital Pathology Solution for Cancer Diagnosis
What You Should Know:
Proscia, a leading provider of digital and computational pathology solutions, has received 510(k) clearance from the United States (U.S.) Food and Drug Administration (FDA) for its Concentriq® AP-Dx*. The digital pathology solution was cleared for the purpose of primary diagnosis.Proscia’s Concentriq AP-Dx is a comprehensive diagnostic software solution that immerses pathologists in an intuitive experience for viewing, interpreting, and managing whole slide images
Read More
